Dose dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

European Journal of Clinical Pharmacology

Volumn 51, Issue 1, 1996, Pages 73-78

  Jeppesen, U ^a   Gram, L F ^a   Vistisen, K ^b   Loft, S ^b   Poulsen, H E ^b   Brosen K ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CYP1A2; CYP2C19; CYP2D6; Inhibition; Single dose; SSRIs

Indexed keywords

CITALOPRAM; CYTOCHROME P450 ISOENZYME; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; FONTEX; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITALOPRAM; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; FLUVOXAMINE; HUMANS; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SPARTEINE;

EID: 0029738965     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050163     Document Type: Article

References (45)

1. Brosen K (1993) The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest 71:1002-1009
2. Brosen K, Gram LF, Kragh Sorensen P (1991) Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit 13:177-182
3. Sindrup SH, Brosen K, Gram LF, et al (1992) The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 51:278-287
4. Brosen K, Skjelbo E (1991) Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism (letter). Br J Clin Pharmacol 32:136-137
5. Skjelbo E, Brosen K (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34:256-261
6. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34:262-265
7. Sindrup SH, Brosen K, Hansen MG, Aaes Jorgensen T, Overo KF, Gram LF (1993) Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15:11-17
8. Brosen K (1995) Are pharmacokinetic drug interaction with the SSRIs an issue? Proceedings from the citalopram launch-conference "Managing depression with the whole patient in mind" in Paris, 2-3 June 1995. In Clin Psychopharmacol [Suppl] (Squared times):(Squared times)
9. Wrighton SA, Stevens JC, Becker GW, Vandenbranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4-hydroxylation. Arch Biochem Biophys 306:240-245
10. Goldstein JA, Faletto MB, Romkes Sparks M, et al (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752
11. Breyer Pfaff U, Pfandl B, Nill K, et al (1992) Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 52:350-358
12. Nielsen KK, Brosen K, Hansen MG, Gram LF (1994) Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 55:518-527
13. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355
14. Skjelbo E, Brosen K, Hallas J, Gram LF (1991) The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 49:18-23
15. Kupfer A, Branch RA (1985) Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clin Pharmacol Ther 38:414-418
16. Gram LF Guentert TW, Grange S, Vistisen K, Brosen K (1995) Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 57:670-677
17. Andersson T, Regardh CG, Dahl Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12:415-416
18. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide anti-malarial proguanil co-segregates with the mephenytoin oxidation polymorphism a panel study. Br J Clin Pharmacol 31:689-692
19. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P450IA2. Biochem Pharmacol 45:1211-1214
20. Rasmussen BB, Maenpaa J, Pelkonen O, et al (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151-159
21. Bertschy G, Vandel S, Vandel B, Allers G, Volmat R (1991) Fluvoxamine-tricyclic antidepressant interaction. An accidental finding (letter). Eur J Clin Pharmacol 40:119-120
22. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281
23. Jerling M, Lindstrom L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368-374
24. Spina E, Campo GM, Avenoso A, Pollicino MA, Caputi AP (1992) Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 14:194-196
25. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243-246
26. Benfield P, Ward A (1986) Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 32:313-334
27. Diot P, Jonville AP, Gerard F, et al (1991) Possible interaction between theophylline and fluvoxamine (letter). Therapie 46:170-171
28. Sperber AD (1991) Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 6:460-462
29. Thomson AH, McGovern EM, Bennie P, Caldwell G, Smith M (1992) Interaction between fluvoxamine and theophylline. Pharm Journal 137:
30. Vinks A, Inaba T, Otton SV, Kalow W (1982) Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 31:23-29
31. Sanz EJ, Villen T, Alm C, Bertilsson L (1989) S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45:495-499
32. Campbell ME, Spielberg SP, Kalow W (1987) A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 42:157-165
33. Vistisen K, Poulsen HE, Loft S (1992) Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 13:1561-1568
34. Jeppesen U, Loft S, Poulsen HH, Brosen K (1995) A fluvoxamine-caffeine interaction study. Pharmacogenetics (in press)
35. Brosen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol Copenh 57:357-360
36. Drohse A, Bathum L, Brosen K, Gram LF (1989) Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol 27:620-625
37. Kalow W, Tang BK (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519
38. Kadlubar FF, Talaska G, Butler MA, Teitel CH, Massengill JP, Lang NP (1990) Determination of carcinogenic arylamine X-oxidation phenotype in humans by analysis of caffeine urinary metabolites. Prog Clin Biol Res 340B:107-114
39. Brosen K, Hansen JG. Nielsen KK, Sindrup SH, Gram LF (1993) Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 44:349-355
40. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxeline. J Clin Psychopharmacol 14:90-98
41. Alderman J, Greenblatt DJ, Allison J, Preskorn SH, Chung M, Harison W (1994) Desipramine pharmacokinetics with the serotonin reuptake inhibitors, paroxetine or sertraline. Abstract presented at the XIX CINP Congress, Washington, 26 June 1 July 1994
42. Palo MT, Murphy DL, DeVane CL (1991) Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation (letter). J Clin Psychopharmacol 11:224-225
43. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 86:7696-7700
44. Sesardic D, Boobis AR, Murray BP, et al. (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651-663
45. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A (1991) Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos Biol Fate Chem 19:561-567